Skip to main content

Research Repository

Advanced Search

New Myrtenal–Adamantane Conjugates Alleviate Alzheimer’s-Type Dementia in Rat Model

Dragomanova, Stela; Lazarova, Maria; Munkuev, Aldar; Suslov, Evgeniy; Volcho, Konstantin; Salakhutdinov, Nariman; Bibi, Amina; Reynisson, Jóhannes; Tzvetanova, Elina; Alexandrova, Albena; Georgieva, Almira; Uzunova, Diamara; Stefanova, Miroslava; Kalfin, Reni; Tancheva, Lyubka

New Myrtenal–Adamantane Conjugates Alleviate Alzheimer’s-Type Dementia in Rat Model Thumbnail


Authors

Stela Dragomanova

Maria Lazarova

Aldar Munkuev

Evgeniy Suslov

Konstantin Volcho

Nariman Salakhutdinov

Amina Bibi

Elina Tzvetanova

Albena Alexandrova

Almira Georgieva

Diamara Uzunova

Miroslava Stefanova

Reni Kalfin

Lyubka Tancheva



Abstract

Alzheimer’s disease (AD) is a neurodegenerative disease associated with memory impairment and other central nervous system (CNS) symptoms. Two myrtenal–adamantane conjugates (MACs) showed excellent CNS potential against Alzheimer’s models. Adamantane is a common pharmacophore for drug design, and myrtenal (M) demonstrated neuroprotective effects in our previous studies. The aim of this study is to evaluate the MACs’ neuroprotective properties in dementia. Methods: Scopolamine (Scop) was applied intraperitoneally in Wistar rats for 11 days, simultaneously with MACs or M as a referent, respectively. Brain acetylcholine esterase (AChE) activity, noradrenaline and serotonin levels, and oxidative brain status determination followed behavioral tests on memory abilities. Molecular descriptors and docking analyses for AChE activity center affinity were performed. Results: M derivatives have favorable physicochemical parameters to enter the CNS. Both MACs restored memory damaged by Scop, showing significant AChE-inhibitory activity in the cortex, in contrast to M, supported by the modeling analysis. Moderate antioxidant properties were manifested by glutathione elevation and catalase activity modulation. MACs also altered noradrenaline and serotonin content in the hippocampus. Conclusion: For the first time, neuroprotective properties of two MACs in a rat dementia model were observed. They were stronger than the natural M effects, which makes the substances promising candidates for AD treatment.

Citation

Dragomanova, S., Lazarova, M., Munkuev, A., Suslov, E., Volcho, K., Salakhutdinov, N., …Tancheva, L. (2022). New Myrtenal–Adamantane Conjugates Alleviate Alzheimer’s-Type Dementia in Rat Model. Molecules, 27(17), Article 5456. https://doi.org/10.3390/molecules27175456

Journal Article Type Article
Acceptance Date Aug 22, 2022
Online Publication Date Aug 25, 2022
Publication Date Aug 25, 2022
Publicly Available Date May 30, 2023
Journal Molecules
Publisher MDPI
Volume 27
Issue 17
Article Number 5456
DOI https://doi.org/10.3390/molecules27175456
Public URL https://keele-repository.worktribe.com/output/424401
Publisher URL https://www.mdpi.com/1420-3049/27/17/5456

Files






You might also like



Downloadable Citations